CDK4/6 inhibitors (CDK4/6i) have become the standard of care for HR+, HER2- advanced breast cancer (ABC), with efforts underway to extend their benefit through combination therapies and for use in additional populations, including those with HER2+ disease (8, 9). Here, ERBB2 is linked to breast carcinoma.